WO2024122444A1 - 含フッ素イソオキサゾール化合物およびその製造方法 - Google Patents

含フッ素イソオキサゾール化合物およびその製造方法 Download PDF

Info

Publication number
WO2024122444A1
WO2024122444A1 PCT/JP2023/042990 JP2023042990W WO2024122444A1 WO 2024122444 A1 WO2024122444 A1 WO 2024122444A1 JP 2023042990 W JP2023042990 W JP 2023042990W WO 2024122444 A1 WO2024122444 A1 WO 2024122444A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
following general
fluorine
represented
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/042990
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
淳弥 清野
理恵 青津
敬介 小金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unimatec Co Ltd
Original Assignee
Unimatec Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unimatec Co Ltd filed Critical Unimatec Co Ltd
Priority to US19/136,732 priority Critical patent/US20260209191A1/en
Priority to EP23900559.8A priority patent/EP4631934A1/en
Priority to JP2024562726A priority patent/JP7774743B2/ja
Priority to CN202380084169.7A priority patent/CN120359206A/zh
Publication of WO2024122444A1 publication Critical patent/WO2024122444A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to a fluorine-containing isoxazole compound and a method for producing the same.
  • Compounds that have an isoxazole ring or its tautomer, an isoxazolone ring, are known to have various pharmacological actions.
  • specific examples of natural products include ibotenic acid and muscimol.
  • pharmaceuticals include ⁇ -lactam antibiotics such as oxacillin and flucloxacillin, sulfonamide antibiotics such as sulfafurazole and sulfamethoxazole, oxazolidinone antibiotics such as posizolid, antirheumatic drugs such as leflunomide and valdecoxib, liver disease treatment drug such as tropifexor, anticancer drug such as tivozanib, antiviral drug such as pleconaril, antidepressant drug such as isocarboxazid, diabetes treatment drug such as glisoxepide, and endometriosis treatment drug such as danazol.
  • pesticides include the insecticide Isoxathion
  • Non-Patent Document 1 reports that compounds having an isoxazole ring substituted with a methoxy group at the 3rd position and a 1-tetrazolyl group at the 5th position have cholinesterase inhibitory activity and are therefore being researched as therapeutic agents for Alzheimer's disease.
  • Non-Patent Document 2 reports that such compounds have agonist activity for the sphingosine-1-phosphate receptor S1P1 and are therefore being researched as drugs to treat autoimmune diseases.
  • fluorine-containing isoxazole compounds that not only have heteroatom substituents at the 3rd and/or 5th positions of the isoxazole ring, but also have a trifluoromethyl group at the 4th position of the isoxazole ring, in the hope that they will be useful as therapeutic agents for various diseases.
  • the present invention provides a novel fluorine-containing isoxazole compound having a trifluoromethyl group at the 4-position on the isoxazolone ring and a heteroatom substituent at the 3-position and/or 5-position, and a method for easily producing the fluorine-containing isoxazole compound.
  • the fluorine-containing isoxazole compound according to this embodiment is represented by the following general formula (A).
  • R represents a hydrogen atom or a substituted or unsubstituted hydrocarbon having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • the method for producing a fluorine-containing isoxazole compound according to this embodiment is as follows: (I) reacting a fluorine-containing compound selected from a fluorine-containing carbonyl compound, a fluoroisobutene derivative, and a fluoroisobutane derivative with hydroxylamine or a salt thereof, and optionally with a compound represented by the following general formula (5) or a salt thereof, or (II) A step of reacting a fluorine-containing compound selected from a fluorine-containing carbonyl compound, a fluoroisobutene derivative, and a fluoroisobutane derivative with an amine salt or an amine compound, and optionally with a compound represented by the following general formula (5) or a salt thereof, to synthesize a fluorine-containing isoxazole compound represented by the following general formula (A): (In the above general formulas (A) and (5), R represents a hydrogen atom or a substituted or unsubstituted hydrocarbon
  • the present invention provides a novel fluorine-containing isoxazole compound having a trifluoromethyl group at the 4-position on the isoxazolone ring and a heteroatom substituent at the 3-position and/or 5-position, and a method for easily producing the fluorine-containing isoxazole compound.
  • a heteroatom substituent is a substituent having a heteroatom, and refers to a functional group containing at least one heteroatom selected from the group consisting of a nitrogen atom (N), a sulfur atom (S), and an oxygen atom (O).
  • the fluorine-containing isoxazole compound in this embodiment is represented by the following general formula (A), and has a trifluoromethyl group at the 4-position on the isoxazole ring and a heteroatom substituent at the 3-position and/or 5-position.
  • R represents a hydrogen atom or a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms or a heterocycle;
  • R represents a substituted or unsubstituted hydrocarbon having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms;
  • the fluorine-containing isoxazole compound represented by general formula (A) is represented by the following general formula (4).
  • R' represents a substituted or unsubstituted hydrocarbon having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • the hydrocarbon groups are not particularly limited as long as they are hydrocarbon groups consisting of carbon atoms and hydrogen atoms having 1 to 12 carbon atoms, and examples thereof include chain hydrocarbon groups, aromatic hydrocarbon groups, and alicyclic hydrocarbon groups.
  • the chain hydrocarbon groups are not particularly limited as long as they have a total of 1 to 12 carbon atoms, and may be straight chain hydrocarbon groups or branched chain hydrocarbon groups, or may be chain hydrocarbon groups having or not having a substituent.
  • the aromatic hydrocarbon groups are not particularly limited as long as they have a total of 6 to 12 carbon atoms, and may be aromatic hydrocarbon groups having or not having a substituent.
  • the aromatic hydrocarbon groups may also have a condensed polycyclic structure.
  • R and R' are alicyclic hydrocarbon groups, the alicyclic hydrocarbon groups are not particularly limited as long as they have a total of 3 to 12 carbon atoms, and may be alicyclic hydrocarbon groups having or not having a substituent.
  • the alicyclic hydrocarbon groups may also have a bridged ring structure.
  • Examples of the chain hydrocarbon group include alkyl groups such as a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group, a decyl group, an undecyl group, and a dodecyl group; alkenyl groups such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, and dodecenyl groups;
  • Examples of the alkynyl group include an ethynyl group, a propyn
  • Aromatic hydrocarbon groups include phenyl and naphthyl groups.
  • Alicyclic hydrocarbon groups include saturated or unsaturated cyclic hydrocarbon groups, and examples of cyclic hydrocarbon groups include cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, adamantyl, and norbornyl groups.
  • one of the hydrogen atoms of the chain hydrocarbon group may be substituted with an alkoxyl group or an aralkyl group.
  • the alkoxyl group is preferably substituted with an alkoxyl group having 1 to 6 carbon atoms, such as a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, an n-pentoxy group, or an n-hexyloxy group.
  • the aralkyl group is preferably substituted with an alkyl group having 1 to 6 carbon atoms, such as a benzyl group, a phenylethyl group, a phenylpropyl group, or a naphthylmethyl group.
  • substituents include the above-mentioned alkyl groups and alkoxy groups having 1 to 6 carbon atoms.
  • the halogen atom is F, Cl, Br or I, and is preferably F or Cl.
  • a 1 , A 2 and A 3 contained in -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ) and -NA 3 -NA 1 A 2 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms.
  • a 1 , A 2 and A 3 may be the same as or different from each other.
  • a 1 , A 2 and A 3 represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • a 1 , A 2 and A 3 are the same as the hydrocarbon group having 1 to 12 carbon atoms defined for R and R' above, and can be, for example, a hydrocarbon group having 1 to 12 carbon atoms among the above R and R'.
  • the hydrocarbon group having 1 to 12 carbon atoms a chain hydrocarbon group having 1 to 12 carbon atoms is preferable, a chain hydrocarbon group having 1 to 10 carbon atoms is more preferable, an alkyl group having 1 to 10 carbon atoms is further preferable, and an alkyl group having 1 to 4 carbon atoms is particularly preferable.
  • the heterocycle is a monocyclic, bicyclic or polycyclic heterocycle which may be optionally substituted and which contains at least one heteroatom selected from the group consisting of a nitrogen atom (N), a sulfur atom (S) and an oxygen atom (O) as a ring atom.
  • the heterocycle may have a plurality of heteroatoms which may be the same or different. It is preferable that the skeleton of each heterocycle contains at least one nitrogen atom as a heteroatom.
  • One of the heteroatoms contained in the heterocycle, preferably N, is directly bonded to the isoxazole ring of the fluorine-containing isoxazole compound and is substituted by the isoxazole ring as a heteroatom substituent.
  • the heterocycle may be a condensed ring, an alicyclic heterocycle or an aromatic heterocycle, or a combination thereof.
  • the monocyclic heterocycle is preferably a 3- to 12-membered ring, and more preferably a 5- to 9-membered ring.
  • the heterocycle may contain up to 5 heteroatoms.
  • Each heteroatom is individually selected from O, S, and N, and preferably at least one of the heteroatoms is N.
  • Examples of monocyclic heterocycles include pyrrolidine, pyrroline, pyrrole, pyrazolidine, imidazolidine, pyrazoline, imidazoline, imidazole, pyrazole, triazole, tetrazole, (iso)oxazole, (iso)oxadiazole, (iso)thiazole, thiadiazole, pyridine, pyrrolidine, piperidine, piperazine, pyridazine, pyrimidine, pyrazine, triazine, thienopyridine, piperazinone, morpholine, thiomorpholine, thiomorpholine dioxide, oxazine, thiazine, azocane, azocine, azonane, azonine, and derivatives thereof.
  • the bicyclic heterocycle is preferably a 7-14 membered ring, more preferably an 8-10 membered ring.
  • the bicyclic heterocycle may also contain a spiro ring.
  • When the heterocycle is a bicyclic heterocycle it may contain up to 10 heteroatoms. Each heteroatom is individually selected from O, S and N, and it is preferred that at least one of the heteroatoms is N.
  • Examples of bicyclic heterocycles include (iso)indole, aza(iso)indole, (aza)indazole, (aza)benzimidazole, (aza)benztriazole, hydrothienopyridine, (iso)quinoline, hydro(iso)quinoline, hydrofuropyridine and derivatives thereof.
  • the polycyclic heterocycle is preferably a 9- to 30-membered ring, and more preferably a 12- to 26-membered ring.
  • the polycyclic heterocycle may also contain a spiro ring.
  • the heterocycle When the heterocycle is a polycyclic heterocycle, it may contain up to 15 heteroatoms. Each heteroatom is individually selected from O, S, and N, and it is preferred that at least one of the heteroatoms is N.
  • Examples of polycyclic heterocycles include carbazole, phenazine, phenoxazine, phenothiazine, benzoindole, pyrroloquinoline, acridine, and derivatives thereof.
  • examples of the substituent include a halogen atom, a C1 - C10 hydrocarbon group, an oxygen-containing substituent such as a hydroxy group, an alkoxy group, a carbonyl group, or a carboxy group, a nitrogen-containing substituent such as an amino group, a cyano group, or a nitro group, or a sulfur-containing substituent such as a sulfanyl group, a sulfoxy group, or a sulfone group.
  • a 1 , A 2 and A 3 are heterocycles, A 1 , A 2 and A 3 are the same as the heterocycle defined for X above.
  • a 1 may be a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms and A 2 may be a heterocycle.
  • X is -NA 1 (OA 2 )
  • a 1 may be a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms and A 2 may be a heterocycle, or A 1 may be a heterocycle and A 2 may be a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms.
  • a 1 and A 3 may be substituted or unsubstituted hydrocarbon groups having 1 to 12 carbon atoms, A 2 may be a heterocycle, or A 1 may be substituted or unsubstituted hydrocarbon groups having 1 to 12 carbon atoms, A 2 and A 3 may be heterocycles.
  • n is preferably 3 to 15, and more preferably 5 to 10.
  • the fluorine-containing isoxazole compound in this embodiment has a specific substituent (-X, -CF 3 , -OR or -OR') on the isoxazole ring, and therefore has an excellent effect in terms of structural expandability, and in particular, further improvement in pharmacological activity can be expected.
  • the 3-position, 4-position and 5-position on the isoxazole ring can have different substituents, respectively, the compound can be easily derivatized to an asymmetric structure, and can be used as an intermediate. More specifically, a derivative can be obtained by modifying -OR or -OR' by reacting the fluorine-containing isoxazole compound under acidic conditions.
  • the substituent X on the isoxazole ring is a halogen atom
  • a derivative can be obtained by modifying the halogen atom by reacting the fluorine-containing isoxazole compound under basic conditions.
  • the fluorine-containing isoxazole compound in this embodiment is also useful in the field of electronic materials such as organic semiconductors and liquid crystals.
  • the method for producing a fluorine-containing isoxazole compound in this embodiment includes a step of (I) reacting a fluorine-containing compound selected from fluorine-containing carbonyl compounds, fluoroisobutene derivatives, and fluoroisobutane derivatives with hydroxylamine or a salt thereof, and optionally with a compound represented by the following general formula (5) or a salt thereof, or (II) reacting a fluorine-containing compound selected from fluorine-containing carbonyl compounds, fluoroisobutene derivatives, and fluoroisobutane derivatives with an amine salt or an amine compound, and optionally with a compound represented by the following general formula (5) or a salt thereof, to synthesize a fluorine-containing isoxazole compound represented by general formula (A).
  • R represents a hydrogen atom or a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • the fluorine-containing isoxazole compound represented by the general formula (A) can be synthesized, for example, by the following method.
  • a first embodiment of the method for producing a fluorinated isoxazole compound in this embodiment includes a step of (a) reacting a fluorinated carbonyl compound represented by the following general formula (6) with a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (1):
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Z represents -OA 5 , -O-NA 5 A 6 , -NA 5 A 6 , -NA 5 (OA 6 ) or -NA 7 -NA 5 A 6 ;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted alkyl group having 1 to 12 carbon atoms.
  • a second embodiment of the method for producing a fluorine-containing isoxazole compound in the present embodiment includes a step of (b) reacting a fluorine-containing carbonyl compound represented by the following general formula (8), a compound represented by the following general formula (5) or a salt thereof, and a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Z represents -OA 5 , -O-NA 6 A 7 , -NA 5 A 6 , -NA 5 (OA 6 ) or -NA 7 -NA 5 A 6 ;
  • a 1 , A 2 and A 3 each independently
  • a third embodiment of the method for producing a fluorine-containing isoxazole compound in the present embodiment includes a step (c) of reacting a fluorine-containing carbonyl compound represented by the following general formula (9) with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then further reacting the obtained reaction product with hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Z represents -OA 5 , -O-NA 6 A 7 , -NA 5 A 6 , -NA 5 (OA 6 ) or -NA 7 -NA 5 A 6
  • a fourth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step (d) of reacting a fluorine-containing carbonyl compound represented by the following general formula (10) with an alcohol, reacting the obtained reaction product with a compound represented by the following general formula (5) in the presence of a base, and then reacting it with hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • A4 represents an alkylene group represented by
  • a fifth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step of (e) carbonylating a fluoroisobutene derivative represented by the following general formula (11) in the presence of a nucleophile, further reacting the resulting reaction product with an alcohol, reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the resulting reaction product with a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2
  • a sixth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step of (f) carbonylating a compound obtained by an elimination reaction of a fluoroisobutane derivative represented by the following general formula (12) in the presence of a nucleophile, further reacting with an alcohol, and then reacting the obtained reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting with hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -
  • a seventh embodiment of the present embodiment for producing a fluorinated isoxazole compound includes a step (g) of reacting a fluorinated carbonyl compound represented by the following general formula (13) with an amine salt or an amine compound to obtain a fluorinated isoxazole compound represented by the following general formula (2):
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • An eighth embodiment of the method for producing a fluorinated isoxazole compound in the present embodiment includes a step (h) of reacting a fluorinated carbonyl compound represented by the following general formula (14), an amine salt or an amine compound, and optionally a compound represented by the following general formula (5) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (2):
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 (OA 2 ), -NA 1 A 2 , -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • a ninth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step of (i) reacting a fluorine-containing carbonyl compound represented by the following general formula (15) with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the obtained reaction product with an amine salt or an amine compound to obtain a fluorine-containing isoxazole compound represented by the following general formula (2):
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12
  • a tenth embodiment of the method for producing a fluorine-containing isoxazole compound in this embodiment includes a step of (j) reacting a fluorine-containing carbonyl compound represented by the following general formula (10) with an alcohol, reacting the obtained reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the resultant with an amine salt or an amine compound, thereby obtaining a fluorine-containing isoxazole compound represented by the following general formula (2):
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or
  • An eleventh embodiment of the method for producing a fluorine-containing isoxazole compound in the present embodiment includes a step of (k) carbonylating a fluoroisobutene derivative represented by the following general formula (11) in the presence of a nucleophile, further reacting the resulting reaction product with an alcohol, reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the resulting product with an amine salt or an amine compound, thereby obtaining a fluorine-containing isoxazole compound represented by the following general formula (2): (In the above general formulas (2), (5) and (11), R and R' each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms; X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2
  • a twelfth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step of (l) carbonylating a compound obtained by an elimination reaction of a fluoroisobutane derivative represented by the following general formula (12) in the presence of a nucleophile, further reacting the compound with an alcohol, reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the resulting reaction product with an amine salt or an amine compound to obtain a fluorine-containing isoxazole compound represented by the following general formula (2):
  • R and R' each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1
  • a thirteenth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step (m) of reacting a fluorine-containing carbonyl compound represented by the following general formula (10) with a hydroxylamine represented by the following general formula (7) or a salt thereof, and further reacting the obtained reaction product with a compound represented by the following general formula (5) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (3):
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • a fourteenth embodiment of the present embodiment for producing a fluorinated isoxazole compound includes a step of (n) carbonylating a fluoroisobutene derivative represented by the following general formula (11) in the presence of a nucleophilic agent, further reacting the resulting compound with a hydroxylamine represented by the following general formula (7) or a salt thereof, and then reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (3):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a fifteenth embodiment of the present embodiment for producing a fluorine-containing isoxazole compound includes a step of (o) carbonylating a fluoroisobutane derivative represented by the following general formula (12) in the presence of a nucleophilic agent, further reacting the resulting compound with a hydroxylamine represented by the following general formula (7) or a salt thereof, and then reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (3):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 -NA 4 or a heterocycle;
  • Y represents a halogen atom, -OA 1
  • a sixteenth embodiment of the present embodiment for producing a fluorinated isoxazole compound includes a step (p) of reacting a fluoroisobutene derivative represented by the following general formula (11), a compound represented by the following general formula (5) or a salt thereof, and a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (4):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 (OA 2 ), -NA 1 A 2 , -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • a seventeenth embodiment of the present embodiment for producing a fluorinated isoxazole compound includes a step (q) of reacting a fluoroisobutene derivative represented by the following general formula (11) with a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (4-1):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms.
  • An eighteenth embodiment of the method for producing a fluorinated isoxazole compound in the present embodiment includes a step of (r) reacting a fluoroisobutane derivative represented by the following general formula (12), a compound represented by the following general formula (5) or a salt thereof, and a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (4):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Y represents a halogen atom, -OB 1 , -SO m B 1 or -NB 1 B 2 ;
  • a nineteenth embodiment of the present embodiment for producing a fluorinated isoxazole compound includes a step (s) of reacting a fluoroisobutane derivative represented by the following general formula (12) with a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorinated isoxazole compound represented by the following general formula (4-1):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • Y represents a halogen atom, -OB 1 , -SO m B 1 or -NB 1 B 2
  • m is an integer from 0 to 3
  • B1 and B2 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms.
  • the fluorine-containing carbonyl compound is preferably a compound represented by the above general formula (6), (8), (9), (10), (13), (14) or (15),
  • the fluoroisobutene derivative is preferably a compound represented by the above general formula (11), and the fluoroisobutane derivative is preferably a compound represented by the above general formula (12).
  • a 1 , A 2 , A 3 and the heterocycle are the same as those defined in the fluorine-containing isoxazole compounds represented by the above general formulae (A) and (1) to (4).
  • R' is the same as that defined in the fluorine-containing isoxazole compound represented by the above general formula (4), and the substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms in R' is preferably an alkyl group having 1 to 10 carbon atoms.
  • a 5 , A 6 and A 7 are the same as the substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms defined for R and R′ above, and the substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms in A 5 , A 6 and A 7 is preferably an alkyl group having 1 to 10 carbon atoms.
  • B 1 and B 2 are the same as the substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms defined above for R and R′.
  • Y represents a halogen atom, -OB 1 , -SO m B 1 or -NB 1 B 2 .
  • the halogen atom is F, Cl, Br or I, and preferably F or Cl.
  • B 1 contained in -OB 1 and -SO m B 1 represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms and is the same as the hydrocarbon group having 1 to 12 carbon atoms defined above for R and R'.
  • m is an integer of 0 to 3, preferably an integer of 0 to 2, and more preferably an integer of 0 to 1.
  • B 1 and B 2 contained in -NB 1 B 2 are each independently a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms. B 1 and B 2 may be the same or different. B 1 and B 2 are the same as the hydrocarbon group having 1 to 12 carbon atoms defined for R and R' above.
  • reaction (a) in the first embodiment is represented as the following reaction formula (A) as a whole.
  • reaction (b) in the second embodiment is represented as the following reaction formula (B) as a whole.
  • reaction (c) in the third embodiment is represented as the following reaction formula (C) as a whole.
  • reaction (d) in the fourth embodiment is represented as the following reaction formula (D) in its entirety:
  • WF represents a salt of cations W + and F- .
  • reaction (e) in the fifth embodiment is shown as the following reaction formula (E) in its entirety.
  • the nucleophile may be represented as "Nu” for convenience.
  • “NuR'F” represents a salt of F- with a cation of the nucleophile in which R' is substituted.
  • reaction (f) in the sixth embodiment is represented as the following reaction formula (F) as a whole.
  • reaction (g) in the seventh embodiment is shown as the following reaction formula (G) in its entirety.
  • reaction formulas (G) to (O) the amine salt or amine compound may be referred to as "N compound" for convenience.
  • reaction (h) in the eighth embodiment is represented as the following reaction formula (H) in its entirety:
  • X in the fluorine-containing isoxazole compound represented by general formula (2) represents a fluorine atom (F).
  • reaction (i) in the ninth embodiment is represented as the following reaction formula (I) as a whole.
  • reaction (j) in the tenth embodiment is represented as the following reaction formula (J) as a whole.
  • reaction (k) in the eleventh embodiment is represented as the following reaction formula (K) as a whole.
  • reaction (l) in the twelfth embodiment is represented as the following reaction formula (L) as a whole.
  • reaction (m) in the thirteenth embodiment is represented as the following reaction formula (M) as a whole.
  • reaction (n) in the fourteenth embodiment is represented as the following reaction formula (N) as a whole.
  • reaction (o) in the fifteenth embodiment is represented as the following reaction formula (O) as a whole.
  • reaction (p) in the sixteenth embodiment is represented as the following reaction formula (P) as a whole.
  • reaction (q) in the seventeenth embodiment is represented as the following reaction formula (Q) as a whole.
  • reaction (r) in the eighteenth embodiment is represented as the following reaction formula (R) as a whole.
  • reaction (s) in the nineteenth embodiment is represented as the following reaction formula (S) as a whole.
  • the hydroxylamine represented by the general formula (7) and the compound represented by the general formula (5) may each be in the form of a salt.
  • the hydroxylamine represented by the general formula (7) is in the form of a salt
  • the portion (-NH 2 ) constituting the amino group of the hydroxylamine is cationized to (-NH 3 + ) to form a salt with a counter ion.
  • the compound represented by the general formula (5) is in the form of a salt
  • the H portion of the compound is cationized to (H + ) to form a salt with a counter ion.
  • the counter ion is not particularly limited as long as it is a monovalent anion, and examples thereof include halide ions such as F - , Cl - , Br - , and I - , trifluoroacetate anion, paratoluenesulfonate anion, trifluoromethanesulfonate anion, nonafluorobutanesulfonic acid, bis(trifluoromethylsulfonyl)imide anion, and tetrafluoroborate anion.
  • halide ions such as F - , Cl - , Br - , and I -
  • trifluoroacetate anion paratoluenesulfonate anion
  • trifluoromethanesulfonate anion trifluoromethanesulfonate anion
  • nonafluorobutanesulfonic acid bis(trifluoromethylsulfonyl)imide anion
  • examples of the amine salt and the amine compound include amine salts of a nitrogen-containing heterocyclic cation having one amino group (-NH 2 ) bonded to a nitrogen atom in a heterocycle or a quaternary ammonium cation having one amino group (-NH 2 ) bonded to a nitrogen atom, and an anion selected from halogens, sulfuric acid, phosphoric acid, sulfonic acid, trifluoroacetic acid, tetrafluoroborate, tetraphenylborate, hexafluoroborate, and sulfonylimide acid; primary amines, hydroxylamines, or amine salts having an anionic substituent or anion selected from halogens, sulfuric acid, phosphoric acid, sulfonic acid, and trifluoroacetic acid; or quaternary ammonium salts substituted with a hydrocarbon group selected from alkyl
  • the nitrogen-containing heterocyclic cation at least one nitrogen atom may be included as a heteroatom in the heterocycle, and may be optionally substituted.
  • the nitrogen atom on the nitrogen-containing heterocycle is directly bonded to one amino group (-NH 2 ), and the nitrogen-containing heterocyclic cation is a monocyclic heterocycle.
  • At least one heteroatom selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom (O) may be further included as an atom constituting the ring on the nitrogen-containing heterocycle.
  • the nitrogen-containing heterocycle is preferably an aromatic heterocycle, and the number of ring members is preferably 5 to 8, and more preferably 5 or 6. Examples of such nitrogen-containing heterocycles include pyridine, 4-dimethylaminopyridine, and 1-methylimidazole.
  • the nitrogen atom of the quaternary ammonium cation is preferably bonded to a hydrocarbon group selected from an alkyl group and an aryl group as another substituent.
  • the alkyl group preferably has 1 to 12 carbon atoms and may be linear or branched.
  • alkyl group examples include a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group, a decyl group, an undecyl group, and a dodecyl group.
  • the aryl group preferably has 6 to 12 carbon atoms and may be substituted with a methyl group or the like. Examples of such an aryl group include a tolyl group and a mesityl group.
  • the anionic substituent or anion is directly bonded to a nitrogen atom constituting the amine. Also, in the hydroxylamine having the above-mentioned anionic substituent or anion, it is preferable that the anionic substituent or anion is directly bonded to an oxygen atom (-O-NH 2 ) constituting the hydroxylamine.
  • the nitrogen atom of the quaternary ammonium salt is substituted with a hydrocarbon group selected from an alkyl group and an aryl group, and is not bonded to an amino group (-NH 2 ).
  • the alkyl group preferably has 1 to 12 carbon atoms, and may be linear or branched.
  • alkyl groups examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl groups.
  • the aryl group preferably has 6 to 12 carbon atoms, and may be substituted with methyl or the like. Examples of such aryl groups include tolyl and mesityl groups.
  • amine salts and amine compounds include 1-aminopyridinium iodide, tetrabutylammonium azide, hydroxylamine-O-sulfonic acid, 1-aminopyridinium mesitylenesulfonate, O-(mesitylenesulfonyl)hydroxylamine, 1,1,1-trimethylhydrazinium trifluoroacetate, etc.
  • nucleophile When a nucleophile is used in each of the above reactions, examples of the nucleophile include tertiary amines such as triethylamine, quinuclidine, and 1,4-diazabicyclo[2.2.2]octane, imidazole derivatives such as 1-methylimidazole, and pyridine derivatives such as pyridine and 4-dimethylaminopyridine.
  • tertiary amines such as triethylamine, quinuclidine, and 1,4-diazabicyclo[2.2.2]octane
  • imidazole derivatives such as 1-methylimidazole
  • pyridine derivatives such as pyridine and 4-dimethylaminopyridine.
  • examples of the base include inorganic compounds such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium fluoride and potassium fluoride, organic nitrogen derivatives such as pyridine, triethylamine, diisopropylethylamine, diazabicyclononene, diazabicycloundecene, methyltriazabicyclodecene, diazabicyclooctane, and phosphorus derivatives such as phosphazene bases.
  • inorganic compounds such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium fluoride and potassium fluoride
  • organic nitrogen derivatives such as pyridine, triethylamine, diisopropylethylamine, diazabicyclononene, diazabicycloundecene, methyltriazabicyclodecene, diazabicyclooctane, and phosphorus derivatives such as
  • the type of alcohol is not particularly limited as long as it can form an ester of the alcohol with 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid, and can be used appropriately depending on the desired isoxazole structure.
  • a hydrogen halide scavenger When hydrogen fluoride (HF) is generated in the method for producing a fluorine-containing isoxazole compound in this embodiment, for example, a hydrogen halide scavenger may be used.
  • a hydrogen halide scavenger By using a hydrogen halide scavenger, the step of recovering hydrogen fluoride can be omitted, and the fluorine-containing isoxazole compound represented by the above general formula (A) can be obtained more simply.
  • a cyclic isoxazole structure is formed between the fluorine-containing carbonyl compound represented by general formula (6) and the amino group of the hydroxylamine represented by general formula (7).
  • X and CF3 of the fluorine-containing carbonyl compound represented by general formula (6) are located at the 3rd and 4th positions of the formed isoxazole structure, respectively, and OH formed due to the formation of the ring structure is located at the 5th position of the isoxazole structure.
  • a cyclic isoxazole structure is formed between the fluorine-containing carbonyl compound represented by general formula (8) and the amino group of the hydroxylamine represented by general formula (7), the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure, and CF3 of the fluorine-containing carbonyl compound represented by general formula (8) is located at the 4-position of the formed isoxazole structure.
  • a cyclic isoxazole structure is formed between the reaction product obtained by reacting a fluorine-containing carbonyl compound represented by general formula (9) with a compound represented by general formula (5) in the presence of a base and the amino group of hydroxylamine represented by general formula (7), the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, and OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF3 of the fluorine-containing carbonyl compound represented by general formula (9) is located at the 4-position of the formed isoxazole structure.
  • a cyclic isoxazole structure is formed between the reaction product obtained by reacting an intermediate reactant obtained by reacting a fluorine-containing carbonyl compound represented by general formula (10) with an alcohol and a compound represented by general formula (5) in the presence of a base and the amino group of hydroxylamine represented by general formula (7), the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, and OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF3 of the fluorine-containing carbonyl compound represented by general formula (10) is located at the 4-position of the formed isoxazole structure.
  • a fluoroisobutene derivative represented by general formula (11) is carbonylated in the presence of a nucleophile, and the intermediate reactant obtained by further reacting with an alcohol is reacted with a compound represented by general formula (5) in the presence of a base to form a cyclic isoxazole structure between the reaction product and the amino group of hydroxylamine represented by general formula (7), the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, and OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF3 of the fluoroisobutene derivative represented by general formula (11) is located at the 4-position of the formed isoxazole structure.
  • a cyclic isoxazole structure is formed between the reaction product obtained by reacting the compound obtained by the elimination reaction of the fluoroisobutane derivative represented by the general formula (12) with the compound represented by the general formula (5) in the presence of a base and the amino group of the hydroxylamine represented by the general formula (7), the compound represented by the general formula (5) is substituted at the 3-position of the isoxazole structure, and the OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF3 of the fluorine-containing carbonyl compound represented by the general formula (12) is located at the 4-position of the formed isoxazole structure.
  • a cyclic isoxazole structure is formed between the fluorine-containing carbonyl compound represented by general formula (13) and the amino group of the amine salt or amine compound.
  • X, CF3 , and OR of the fluorine-containing carbonyl compound represented by general formula (13) are located at the 3-, 4-, and 5-positions of the formed isoxazole structure, respectively.
  • a cyclic isoxazole structure is formed between the fluorine-containing carbonyl compound represented by general formula (14) and the amino group of the amine salt or amine compound.
  • CF3 and OR of the fluorine-containing carbonyl compound represented by general formula (14) are located, respectively.
  • a cyclic isoxazole structure is formed between the reaction product obtained by reacting a fluorine-containing carbonyl compound represented by general formula (15) with a compound represented by general formula (5) in the presence of a base and the amino group of the amine salt or amine compound, and the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure.
  • CF3 and OR of the fluorine-containing carbonyl compound represented by general formula (15) are located at the 4-position and 5-position of the formed isoxazole structure, respectively.
  • a cyclic isoxazole structure is formed between the reaction product obtained by reacting an intermediate reactant obtained by reacting a fluorine-containing carbonyl compound represented by general formula (10) with an alcohol with a compound represented by general formula (5) in the presence of a base and the amino group of an amine salt or an amine compound, and the compound represented by general formula (5) is substituted at the 3rd position of the isoxazole structure.
  • CF3 possessed by the fluorine-containing carbonyl compound represented by general formula (10) is located at the 4th position of the formed isoxazole structure.
  • OR possessed by the intermediate reactant obtained by reacting a fluorine-containing carbonyl compound represented by general formula (10) with an alcohol (ROH) is located.
  • a fluoroisobutene derivative represented by general formula (11) is carbonylated in the presence of a nucleophile, and the intermediate reactant obtained by further reacting with an alcohol is reacted with a compound represented by general formula (5) in the presence of a base to form a cyclic isoxazole structure between the reaction product obtained and the amino group of an amine salt or an amine compound, and the compound represented by general formula (5) is substituted at the 3rd position of the isoxazole structure.
  • CF3 of the fluorine-containing carbonyl compound represented by general formula (11) is located at the 5th position of the isoxazole structure.
  • OR of the intermediate reactant obtained by reacting the compound obtained by carbonylating the fluoroisobutene derivative represented by general formula (11) with an alcohol (ROH) is located.
  • a compound obtained by the elimination reaction of a fluoroisobutane derivative represented by general formula (12) is carbonylated in the presence of a nucleophile, and the intermediate reactant obtained by further reacting with an alcohol is reacted with a compound represented by general formula (5) in the presence of a base to form a cyclic isoxazole structure between the reaction product obtained and the amino group of an amine salt or an amine compound, and the compound represented by general formula (5) is substituted at the 3rd position of the isoxazole structure.
  • CF3 of the fluorine-containing carbonyl compound represented by general formula (12) is located at the 4th position of the formed isoxazole structure.
  • OR of the intermediate reactant obtained by the reaction of the compound obtained by performing the elimination reaction of a fluoroisobutene derivative represented by general formula (12) and further carbonylating it with an alcohol (ROH) is located.
  • a cyclic isoxazole structure is formed between the fluorine-containing carbonyl compound represented by general formula (10) and the amino group of the hydroxylamine represented by general formula (7).
  • the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, and OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF3 of the fluorine-containing carbonyl compound represented by general formula (10) is located at the 4-position of the formed isoxazole structure.
  • a fluoroisobutene derivative represented by general formula (11) is carbonylated in the presence of a nucleophile, and the intermediate reactant obtained by further reacting with an alcohol is reacted with a compound represented by general formula (5) in the presence of a base to form a cyclic isoxazole structure between the reaction product and the amino group of hydroxylamine represented by general formula (7).
  • the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, and OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF3 of the fluoroisobutene derivative represented by general formula (11) is located at the 4-position of the formed isoxazole structure.
  • a compound obtained by the elimination reaction of a fluoroisobutane derivative represented by general formula (12) is carbonylated in the presence of a nucleophile, and the intermediate reactant obtained by further reacting with an alcohol is reacted with a compound represented by general formula (5) in the presence of a base to form a cyclic isoxazole structure between the reaction product and the amino group of hydroxylamine represented by general formula (7).
  • the compound represented by general formula (5) is substituted at the 3-position of the isoxazole structure, and OH formed due to the formation of the ring structure is located at the 5-position of the isoxazole structure.
  • CF 3 of the fluoroisobutene derivative represented by general formula (12) is located at the 4-position of the formed isoxazole structure.
  • a cyclic isoxazole structure is formed between the fluoroisobutylene derivative represented by general formula (11) and the amino group of the hydroxylamine represented by general formula (7), and the compound represented by general formula (5) is substituted on the isoxazole structure.
  • -OR' and CF3 of the fluoroisobutylene derivative are located at the 3rd and 4th positions, respectively, of the formed isoxazole structure, and X of the compound represented by general formula (5) is located at the 5th position of the isoxazole structure.
  • a cyclic isoxazole structure is formed between the fluoroisobutane derivative represented by general formula (12) and the amino group of the hydroxylamine represented by general formula (7), and the compound represented by general formula (5) is substituted on the isoxazole structure.
  • -OR' and CF3 of the fluoroisobutane derivative are located at the 3rd and 4th positions, respectively, of the formed isoxazole structure, and X of the compound represented by general formula (5) is located at the 5th position of the isoxazole structure.
  • Hydrogen halide scavengers are substances that have the function of capturing the hydrogen fluoride (HF) that is produced.
  • hydrogen halide scavengers include inorganic compounds such as sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium fluoride, and potassium fluoride, organic nitrogen derivatives such as pyridine, triethylamine, diisopropylethylamine, diazabicyclononene, diazabicycloundecene, methyltriazabicyclodecene, and diazabicyclooctane, and phosphorus derivatives such as phosphazene bases.
  • the above reactions (a) to (s) may be carried out in the presence of a fluoride ion trapping agent, if necessary.
  • the fluoride ion trapping agent is preferably a salt of a cation of lithium, sodium, magnesium, potassium, calcium or tetramethylammonium with an anion of trifluoroacetic acid, heptafluorobutyric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, trifluoromethanesulfonic acid, nonafluorobutanesulfonic acid, bis(trifluoromethanesulfonyl)imide, bis(nonafluorobutanesulfonyl)imide, N,N-hexafluoropropane-1,3-disulfonylimide, tetraphenylboric acid, tetrakis[3,5-bis(
  • the cations derived from the fluoride ion scavenger capture the fluorine ions liberated during the reaction and precipitate as a salt with low solubility in organic solvents, accelerating the reaction, which is believed to enable the production of fluorine-containing isoxazole compounds in high yields.
  • the reaction temperature in the above reactions (a) to (s) is preferably 0 to 100°C, more preferably 5 to 50°C, and even more preferably 10 to 20°C.
  • the reaction time in the above reactions (a) to (s) is preferably 0.5 to 48 hours, more preferably 1 to 36 hours, and even more preferably 2 to 12 hours.
  • the solvent used in the above reactions (a) to (s) is preferably an organic solvent, such as aprotic polar solvents such as tetrahydrofuran, monoglyme, diglyme, triglyme, tetraglyme, acetonitrile, dimethylformamide, dimethylacetamide, methylpyrrolidone, 4-methyltetrahydropyran, dimethylethyleneurea, tetramethylurea, dimethylsulfoxide, and sulfolane, or a two-phase solvent consisting of a protic polar solvent such as methanol or water and a non-aqueous solvent such as dichloromethane, toluene, and diethyl ether.
  • aprotic polar solvents such as tetrahydrofuran, monoglyme, diglyme, triglyme, tetraglyme, acetonitrile, dimethylformamide, dimethylacetamide, methylpyrrolidone, 4-
  • quaternary ammonium halides such as benzyltriethylammonium chloride, quaternary phosphonium halides, crown ethers, and the like can be used as desired.
  • R represents a hydrogen atom or a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • R represents a substituted or unsubstituted hydrocarbon having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • R' represents a substituted or unsubstituted hydrocarbon having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Z represents -OA 5 , -O-NA 5 A 6 , -NA 5 A 6 , -NA 5 (OA 6 ), or -NA 7 -NA 5 A 6 ;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or hetero
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Z represents -OA 5 , -O-NA 6 A 7 , -NA 5 A 6 , -NA 5 (OA 6 ) or -NA 7 -NA 5 A 6 ;
  • a 1 , A 2 and A 3 each
  • a method for producing a fluorine-containing isoxazole compound according to the above item [6], comprising the steps of reacting a fluorine-containing carbonyl compound represented by the following general formula (9) with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then further reacting the resulting reaction product with a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Z represents -OA 5 , -O-NA 6 A 7 , -NA 5 A 6 , -NA 5 (OA 6 ) or -NA 7 -NA
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 (OA 2 ), -NA 1 A 2 , -NA 3 -NA 1 A 2
  • a method for producing a fluorine-containing isoxazole compound according to the above item [6], comprising the steps of carbonylating a compound obtained by an elimination reaction of a fluoroisobutane derivative represented by the following general formula (12) in the presence of a nucleophile, further reacting the compound with an alcohol, reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the resulting reaction product with a hydroxylamine represented by the following general formula (7) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (1):
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 (OA 2 ), -NA 1 A 2 , -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • A4 represents an alky
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a hydrogen atom, a substituted or unsubstituted
  • a method for producing a fluorine-containing isoxazole compound according to the above item [6], comprising the steps of reacting a fluorine-containing carbonyl compound represented by the following general formula (10) with an alcohol, reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof in the presence of a base, and then reacting the resulting reaction product with an amine salt or an amine compound to obtain a fluorine-containing isoxazole compound represented by the following general formula (2):
  • R represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or un
  • R and R' each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -
  • R and R' each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A
  • a method for producing a fluorine-containing isoxazole compound according to the above item [6], comprising the steps of reacting a fluorine-containing carbonyl compound represented by the following general formula (10) with a hydroxylamine represented by the following general formula (7) or a salt thereof, and further reacting the obtained reaction product with a compound represented by the following general formula (5) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (3).
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group or heterocycle having 1 to 12 carbon atoms;
  • a method for producing a fluorine-containing isoxazole compound according to the above item [6], comprising the steps of carbonylating a fluoroisobutene derivative represented by the following general formula (11) in the presence of a nucleophilic agent, further reacting the derivative with a hydroxylamine represented by the following general formula (7) or a salt thereof, and then reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (3).
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • a method for producing a fluorine-containing isoxazole compound according to the above item [6], comprising the steps of carbonylating a fluoroisobutane derivative represented by the following general formula (12) in the presence of a nucleophilic agent, further reacting the derivative with a hydroxylamine represented by the following general formula (7) or a salt thereof, and then reacting the resulting reaction product with a compound represented by the following general formula (5) or a salt thereof to obtain a fluorine-containing isoxazole compound represented by the following general formula (3).
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 -NA 4 or a heterocycle
  • Y represents a halogen atom, -OB 1 , -SO m B 1 or -NB 1 B 2 ;
  • m is an integer from 0 to 3;
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms;
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 (OA 2 ), -NA 1 A 2 , -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • a 1 , A 2 and A 3 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms.
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • X represents a halogen atom, -OA 1 , -O-NA 1 A 2 , -NA 1 A 2 , -NA 1 (OA 2 ), -NA 3 -NA 1 A 2 , -NA 4 or a heterocycle
  • Y represents a halogen atom, -OB 1 , -SO m B 1 or -NB 1 B 2 ;
  • R' represents a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms
  • Y represents a halogen atom, -OB 1 , -SO m B 1 or -NB 1 B 2
  • m is an integer from 0 to 3
  • B1 and B2 each independently represent a substituted or unsubstituted hydrocarbon group having 1 to 12 carbon atoms.
  • room temperature described below is in the range of 20°C ⁇ 10°C.
  • Example 1 Preparation of 3-methoxy-4-(trifluoromethyl)-5-hydroxyisoxazole 1.0 g (14 mmol) of hydroxylamine hydrochloride was dissolved in 75 g of methanol under ice-water cooling. Subsequently, 5.7 g (56 mmol) of triethylamine was added dropwise so that the internal temperature did not exceed 10°C. Next, 2.7 g (14 mmol) of methyl 3,3-difluoro-2-(trifluoromethyl)acrylate was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • Example 2 Preparation of 3-ethoxy-4-(trifluoromethyl)-5-hydroxyisoxazole 1.0 g (14 mmol) of hydroxylamine hydrochloride was dissolved in 75 g of ethanol under ice-water cooling. Subsequently, 5.7 g (56 mmol) of triethylamine was added dropwise so that the internal temperature did not exceed 10°C. Next, 2.7 g (14 mmol) of methyl 3,3-difluoro-2-(trifluoromethyl)acrylate was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • Example 3 Preparation of 3-(dibenzylamino)-4-(trifluoromethyl)-5-hydroxyisoxazole 3.9 g (47 mmol) of 1-methylimidazole was added to 20 g of tetrahydrofuran under ice-water cooling. Then, 10 g (47 mmol) of 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture containing a salt of 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid fluoride anion and 1,3-dimethylimidazolium cation was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 5.6 g (47 mmol) of 2-(2-methoxyethoxy)ethanol and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • a reaction mixture containing 2-(2-methoxyethoxy)ethyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 9.3 g (47 mmol) of dibenzylamine, 9.5 g (94 mmol) of triethylamine, and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the mixture was heated to room temperature. After about 16 hours, a reaction mixture containing 2-(2-methoxyethoxy)ethyl (E/Z)-3-(dibenzylamino)-3-fluoro-2-(trifluoromethyl)acrylate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 1.6 g (47 mmol) of hydroxylamine, 9.5 g (94 mmol) of triethylamine, and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the mixture was heated to room temperature. After about 16 hours, a 1N aqueous hydrochloric acid solution was added so that the pH of the reaction mixture became about 5, and ammonium chloride was added until the mixture was saturated.
  • the isolated yield of the obtained compound was 3%.
  • Example 4 Preparation of 3-(dibenzylamino)-4-(trifluoromethyl)-5-hydroxyisoxazole using methyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate instead of 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene in Example 3.
  • 1.9 g (9.5 mmol) of dibenzylamine and 1.9 g (19 mmol) of triethylamine were added to 30 g of tetrahydrofuran under ice water cooling.
  • Example 5 Preparation of 3-(1-azonanyl)-4-(trifluoromethyl)-5-hydroxyisoxazole 3.6 g (30 mmol) of 2-(2-methoxyethoxy)ethanol was added to 30 g of tetrahydrofuran under ice-water cooling. Then, 10 g (30 mmol) of a salt of 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid fluoride anion and 1-methyl-4-dimethylaminopyridinium cation was added dropwise to a mixed solution of 30 g of tetrahydrofuran so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture containing 2-(2-methoxyethoxy)ethyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 3.8 g (30 mmol) of azonan, 6.1 g (60 mmol) of triethylamine, and 30 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture containing 2-(2-methoxyethoxy)ethyl (E/Z)-3-(1-azonanyl)-3-fluoro-2-(trifluoromethyl)acrylate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 1.0 g (30 mmol) of hydroxylamine, 6.1 g (60 mmol) of triethylamine, and 30 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • a 1N aqueous hydrochloric acid solution was added so that the pH of the reaction mixture became about 5, and ammonium chloride was added until it was saturated.
  • the isolation yield of the obtained compound was 11%.
  • Example 6 Preparation of 3-(1-azonanyl)-4-(trifluoromethyl)-5-hydroxyisoxazole using (E/Z)-3-(1-azonanyl)-3-fluoro-2-(trifluoromethyl)acrylate instead of the salt of 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid fluoride anion and 1-methyl-4-dimethylaminopyridinium cation in Example 5.
  • 1.9 g (27 mmol) of hydroxylamine hydrochloride was dissolved in 60 g of methanol under ice-water cooling. Then, 8.2 g (81 mmol) of triethylamine was added dropwise so that the internal temperature did not exceed 10°C.
  • reaction mixture containing 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 8.7 g (86 mmol) of triethylamine and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • a reaction mixture containing a salt of 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid fluoride anion and triethylmethylammonium cation was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 10 g (86 mmol) of 2-(2-methoxyethoxy)ethanol and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the mixture was heated to room temperature. After about 8 hours, a reaction mixture containing 2-(2-methoxyethoxy)ethyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 12 g (86 mmol) of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine, 22 g (172 mmol) of diisopropylethylamine, and 40 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the mixture was heated to room temperature. After about 16 hours, a reaction mixture containing 2-(2-methoxyethoxy)ethyl (E/Z)-3-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-3-fluoro-2-(trifluoromethyl)acrylate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 2.8 g (86 mmol) of hydroxylamine, 22 g (172 mmol) of diisopropylethylamine, and 30 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature. After about 16 hours, a 1N aqueous hydrochloric acid solution was added so that the pH of the reaction mixture became about 5, and ammonium chloride was added until it was saturated.
  • the isolation yield of the obtained compound was 2%.
  • Example 9 Preparation of 3-fluoro-5-methoxy-4-(trifluoromethyl)isoxazole Under ice-water cooling, 0.6 g (3.0 mmol) of methyl 3,3-difluoro-2-(trifluoromethyl)acrylate was added to 20 g of tetrahydrofuran. Then, a solution of 0.9 g (3.0 mmol) of tetrabutylammonium azide dissolved in 20 g of tetrahydrofuran was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • Example 10 Preparation of 4-(3-(5-methoxy-4-(trifluoromethyl))isoxazolyl)thiomorpholine 1,1-dioxide Under ice-water cooling, 0.3 g (2.0 mmol) of thiomorpholine 1,1-dioxide and 0.5 g (4.0 mmol) of diisopropylethylamine were added to 20 g of tetrahydrofuran. Then, 0.4 g (2.0 mmol) of methyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture was cooled with ice-water, and a mixed solution of 1.2 g (9.0 mmol) of 4-methoxybenzyl alcohol, 1.8 g (18.0 mmol) of triethylamine, and 30 g of tetrahydrofuran was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • Example 12 Preparation of 3-amino-5-((2-ethylhexyl)oxy)-N-methyl-N-(3-pyridyl)-4-(trifluoromethyl)isoxazole Under ice-water cooling, 3.9 g (47.0 mmol) of 1-methylimidazole was added to 20 g of tetrahydrofuran. Subsequently, 10 g (47.0 mmol) of 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture containing a salt of 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid fluoride anion and 1,3-dimethylimidazolium cation was obtained. Under ice-water cooling, this reaction mixture was added dropwise to a mixed solution of 6.1 g (47.0 mmol) of 2-ethyl-1-hexanol and 20 g of tetrahydrofuran so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature. After about 8 hours, a reaction mixture containing 2-ethylhexyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 5.1 g (47.0 mmol) of 3-(methylamino)pyridine, 9.5 g (94.0 mmol) of triethylamine, and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the mixture was warmed to room temperature.
  • this reaction mixture was added dropwise to a mixed solution of 10 g (47.0 mmol) of o-(mesitylenesulfonyl)hydroxylamine, 9.5 g (94.0 mmol) of triethylamine, and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the mixture was warmed to room temperature.
  • a 1N aqueous hydrochloric acid solution was added so that the pH of the reaction mixture became about 5, and ammonium chloride was added until the mixture was saturated.
  • the isolated yield of the obtained compound was 3%.
  • Example 13 Preparation of 4-(3-(5-(2-methoxy)ethoxy-4-(trifluoromethyl))isoxazolyl)-2-piperazinone Under ice-water cooling, 20 g (86.0 mmol) of 1,1,1,3,3-pentafluoro-3-methoxy-2-trifluoromethyl-propane was added to 80 g of tetrahydrofuran. Subsequently, 11 g (86.0 mmol) of diisopropylethylamine was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture containing 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene was obtained. Under ice-water cooling, this reaction mixture was added dropwise to a mixed solution of 9.6 g (86.0 mmol) of quinuclidine and 20 g of tetrahydrofuran so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature. After about 8 hours, a reaction mixture containing a salt of 3,3,3-trifluoro-2-(trifluoromethyl)propanoic acid fluoride anion and N-methylquinuclidinium cation was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 6.5 g (86.0 mmol) of 2-methoxyethanol and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature. After about 8 hours, a reaction mixture containing 2-methoxyethyl 3,3,3-trifluoro-2-(trifluoromethyl)propanoate was obtained.
  • This reaction mixture was added dropwise to a mixed solution of 8.6 g (86.0 mmol) of piperazinone, 22 g (172.0 mmol) of diisopropylethylamine, and 40 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • this reaction mixture was added dropwise to a mixed solution of 16 g (86.0 mmol) of 1,1,1-trimethylhydrazinium trifluoroacetate, 22 g (172.0 mmol) of diisopropylethylamine, and 30 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • a 1N aqueous hydrochloric acid solution was added so that the pH of the reaction mixture became about 5, and ammonium chloride was added until it became saturated.
  • the isolation yield of the obtained compound was 2%.
  • the reaction mixture was cooled with ice water, and added dropwise to a mixed solution of 0.8 g (6.4 mmol) of 1,2,3-benzotriazole, 2.3 g (23.0 mmol) of triethylamine, and 30 g of tetrahydrofuran so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • the isolated yield of the obtained compound was 17%.
  • Example 15 Preparation of 5-(10H-spiro[acridine-9,9'-fluoren]-10-yl)-4-(trifluoromethyl)isoxazol-3-ol. Under ice-water cooling, 0.9 g (8.5 mmol) of triethylamine was added to 20 g of acetonitrile. Subsequently, 1.8 g (8.5 mmol) of 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • the reaction mixture was cooled with ice-water, and 0.9 g (8.5 mmol) of triethylamine was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • the reaction mixture was added dropwise to a mixed solution of 2.8 g (8.5 mmol) of 10H-spiro[acridine-9,9'-fluorene], 3.0 g (30.0 mmol) of triethylamine, and 20 g of acetonitrile while cooling with ice water so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • the isolated yield of the obtained compound was 10%.
  • reaction mixture was added dropwise to a mixed solution of 0.6 g (4.8 mmol) of 4-dimethylaminopyridine and 15 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture was added dropwise to a mixed solution of 1.5 g (4.8 mmol) of hydroxylammonium bistrifluoromethanesulfonylimide and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • reaction mixture was cooled with ice-water, and 0.6 g (4.8 mmol) of diisopropylethylamine was added dropwise to the mixed solution of 0.7 g (4.8 mmol) of 2,2,4,4-tetramethyl-3-pentanoneimine, 2.8 g (22.0 mmol) of diisopropylethylamine, and 20 g of tetrahydrofuran under ice-water cooling so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • the isolated yield of the obtained compound was 2%.
  • Example 19 5-fluoro-3-methoxy-4-trifluoromethylisoxazole was produced using 1,1,1,3,3-pentafluoro-3-methoxy-2-trifluoromethyl-propane instead of 1,3,3,3-tetrafluoro-1-methoxy-2-trifluoromethyl-1-propene in Example 17. Hydroxylammonium bis(trifluoromethylsulfonyl)amine 3.1g (10mmol) and 1,1,1,3,3-pentafluoro-3-methoxy-2-trifluoromethyl-propane 23g (10mmol) were added to 4-methyltetrahydropyran 75g under ice-water cooling.
  • a solution of tert-butylimino-tris(dimethylamino)phosphorane 7.1g (30mmol) dissolved in 4-methyltetrahydropyran 25g was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • the mixture was cooled with ice water, and a solution of 6.1 g (26 mmol) of tert-butylimino-tris(dimethylamino)phosphorane in 20 g of 4-methyltetrahydropyran was added dropwise so that the internal temperature did not exceed 10°C, and the temperature was raised to room temperature.
  • Example 19 the isolation yield of the obtained compound was not calculated, but an increase in the type and amount of impurities is predicted due to by-products that may be generated in the process of producing 1,3,3,3-tetrafluoro-1-methoxy-2-(trifluoromethyl)-1-propene in the system from 1,1,1,3,3-pentafluoro-3-methoxy-2-(trifluoromethyl)-propane. Therefore, it is considered that the isolation yield of the obtained product is higher in the production method of Example 17 than in the corresponding production method of Example 19.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/JP2023/042990 2022-12-09 2023-11-30 含フッ素イソオキサゾール化合物およびその製造方法 Ceased WO2024122444A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US19/136,732 US20260209191A1 (en) 2022-12-09 2023-11-30 Fluorine-containing isoxazole compound and method for producing same
EP23900559.8A EP4631934A1 (en) 2022-12-09 2023-11-30 Fluorine-containing isoxazole compound and method for producing same
JP2024562726A JP7774743B2 (ja) 2022-12-09 2023-11-30 含フッ素イソオキサゾール化合物およびその製造方法
CN202380084169.7A CN120359206A (zh) 2022-12-09 2023-11-30 含氟异恶唑化合物及其制造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-197216 2022-12-09
JP2022197216 2022-12-09

Publications (1)

Publication Number Publication Date
WO2024122444A1 true WO2024122444A1 (ja) 2024-06-13

Family

ID=91379184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/042990 Ceased WO2024122444A1 (ja) 2022-12-09 2023-11-30 含フッ素イソオキサゾール化合物およびその製造方法

Country Status (5)

Country Link
US (1) US20260209191A1 (cg-RX-API-DMAC7.html)
EP (1) EP4631934A1 (cg-RX-API-DMAC7.html)
JP (1) JP7774743B2 (cg-RX-API-DMAC7.html)
CN (1) CN120359206A (cg-RX-API-DMAC7.html)
WO (1) WO2024122444A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026033901A1 (ja) * 2024-08-06 2026-02-12 ユニマテック株式会社 含フッ素プロペン酸化合物およびその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454186A (zh) * 2019-01-18 2020-07-28 山东省联合农药工业有限公司 一种含五氟硫基的芳基甲酰苯胺类化合物及其制备方法与用途
WO2021095577A1 (ja) * 2019-11-14 2021-05-20 ユニマテック株式会社 含フッ素ピラゾール化合物およびその製造方法
WO2022230599A1 (ja) * 2021-04-27 2022-11-03 ユニマテック株式会社 含フッ素ピラゾール化合物およびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454186A (zh) * 2019-01-18 2020-07-28 山东省联合农药工业有限公司 一种含五氟硫基的芳基甲酰苯胺类化合物及其制备方法与用途
WO2021095577A1 (ja) * 2019-11-14 2021-05-20 ユニマテック株式会社 含フッ素ピラゾール化合物およびその製造方法
WO2022230599A1 (ja) * 2021-04-27 2022-11-03 ユニマテック株式会社 含フッ素ピラゾール化合物およびその製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, 2016, pages 2470 - 2474
MOHD ABDUL FATAH ABDUL MANAN; DAVID B. CORDES; ALEXANDRA M. Z. SLAWIN; MICHAEL BÜHL; VIVIAN W. Y. LIAO; HAN. C. CHUA; MARY CHEBIB;: "The Synthesis and Evaluation of Fluoro‐, Trifluoromethyl‐, and Iodomuscimols as GABA Agonists", CHEMISTRY - A EUROPEAN JOURNAL, JOHN WILEY & SONS, INC, DE, vol. 23, no. 45, 24 July 2017 (2017-07-24), DE, pages 10848 - 10852, XP071843305, ISSN: 0947-6539, DOI: 10.1002/chem.201701443 *
NEW JOURNAL OF CHEMISTRY, vol. 39, 2015, pages 2028 - 2041
See also references of EP4631934A1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026033901A1 (ja) * 2024-08-06 2026-02-12 ユニマテック株式会社 含フッ素プロペン酸化合物およびその製造方法

Also Published As

Publication number Publication date
JP7774743B2 (ja) 2025-11-21
JPWO2024122444A1 (cg-RX-API-DMAC7.html) 2024-06-13
CN120359206A (zh) 2025-07-22
US20260209191A1 (en) 2026-07-23
EP4631934A1 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
KR102482289B1 (ko) 중수소화 아미드 및 중수소화 설폰아미드의 신규 합성방법
US8003784B2 (en) Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
JP6523334B2 (ja) 置換サイクロセリンの調製のための方法
CN114555581B (zh) 含氟吡唑化合物及其制备方法
CN101910159A (zh) 杂环取代吡啶衍生物的制备方法
JP7774743B2 (ja) 含フッ素イソオキサゾール化合物およびその製造方法
CN115210233A (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
AU2018311307B2 (en) Crystalline forms of hydroxynorketamine
KR20100046026A (ko) 4-페닐-6-(2,2,2-트리플루오로-1-페닐에톡시)피리미딘-기재화합물의 제조 방법
De-la-Torre et al. Ultrasound-assisted phase-transfer catalysis method in an aqueous medium to promote the Knoevenagel reaction: Advantages over the conventional and microwave-assisted solvent-free/catalyst-free method
JP7614331B2 (ja) 含フッ素ピリミジン化合物およびその製造方法
JP7595153B2 (ja) 含フッ素ピラゾール化合物およびその製造方法
CN102260252A (zh) 可用于治疗细菌感染的新噁唑烷酮
JP7349551B2 (ja) 含フッ素ピリミジン化合物およびその製造方法
EP2639235B1 (en) Pyrazino[2,3-d]isooxazole derivative
JP2012514630A5 (cg-RX-API-DMAC7.html)
WO2026033901A1 (ja) 含フッ素プロペン酸化合物およびその製造方法
CN107954918A (zh) 一种n-氘代甲基吲哚类化合物的合成方法
JP7649872B2 (ja) 含フッ素ピラゾール化合物およびその製造方法
WO2024166973A1 (ja) 含フッ素ピラゾロン化合物およびその製造方法
JPWO2012157504A1 (ja) β−ラクタム化合物およびその製造方法
JP2026054622A (ja) 含フッ素プロペン酸化合物の製造方法
CN106380410A (zh) 3‑氯‑4‑烷氧基苯胺类化合物的制备方法
WO2010092286A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
EP2719684A1 (en) Method of manufacturing benzylamine compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23900559

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024562726

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202380084169.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 202537059758

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2023900559

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023900559

Country of ref document: EP

Effective date: 20250709

WWP Wipo information: published in national office

Ref document number: 202537059758

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 202380084169.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023900559

Country of ref document: EP